PRSS2 and neoplasm: Strikingly, the knockdown of PRSS2 in tumor cells and knockout of LRP1 in myeloid cells potently inhibited tumor growth in mouse models of breast and pancreatic cancer, with tumors having higher levels of Tsp-1 in the TME.